Understanding why some lung cancer patients don't respond to immunotherapy
Official title: Deciphering LKB1-associated immunotherapy resistance in lung adenocarcinoma (LUAD)
Funded at Emory University · NIH-10861801 · Data updated 2026-11-12
This study is looking into why some patients with lung cancer and LKB1 gene mutations don’t respond well to immunotherapy, and it hopes to find new ways to boost their immune systems to fight the cancer better.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | June 1, 2022 |
| Project end | May 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $2,055,632 |
| NIH project number | 5P01CA257906-03 |
| Project ID | NIH-10861801 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with lung adenocarcinoma who have LKB1 mutations.
✕Less likely to help
Patients without LKB1 mutations or those with other types of lung cancer may not benefit from this research.
What this research studies
This research investigates the reasons behind the resistance to immunotherapy in patients with lung adenocarcinoma who have mutations in the LKB1 gene. The team aims to develop personalized treatment strategies by exploring how these mutations affect tumor growth and immune response. They will utilize advanced techniques to analyze the metabolic changes and immune suppression caused by LKB1 loss, with the goal of identifying new therapeutic options that could enhance the effectiveness of existing treatments. Patients with LKB1 mutations may benefit from innovative approaches that reactivate their immune systems against cancer.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for lung cancer patients with LKB1 mutations, improving their response to immunotherapy.
How similar studies have gone: Previous research has shown promising results in targeting specific genetic mutations in cancer, indicating potential for success in this novel approach.
Where this research is happening
-
Emory University
Atlanta, United States Active
Researchers
- Principal investigator: Fu, Haian — Emory University
- Study coordinator: Fu, Haian
Related research
Other NIH-funded projects on the same topics.
-
LKB1-linked immune resistance in lung cancer and new therapies
Researchers are testing new ways to treat a common lung cancer subtype by targeting how LKB1 mutations suppress the immune response and make tumors harder to treat.
-
Understanding a highly flexible cell state in lung cancer that worsens outcomes
A doctor-scientist at Cedars-Sinai wants to learn how a highly adaptable lung cancer cell state drives disease progression and resistance to therapy, using models that resemble human tumors.
-
Overcoming Immunotherapy Resistance in Metastatic Gastric/Esophageal Cancer
A Mayo Clinic-led study aims to find better combos of immune therapy and standard treatment to help people with metastatic gastric and esophageal cancer who don’t respond well to current options.
-
In vivo B7-H3 CAR-T cells for pancreatic cancer therapy
A patient-friendly look at a new approach that aims to produce CAR-T cells directly inside the body to target pancreatic cancer.
-
Novel combo therapy using oncolytic adenovirus and immune drugs for pancreatic cancer
Aims to combine an oncolytic virus with immune therapies to help shrink pancreatic tumors before surgery and keep them from coming back.
-
Breaking cytokine loops in LKB1-mutant lung cancer and the immune system
A researcher at NYU School of Medicine is studying why a common lung cancer subtype with a specific mutation doesn’t respond well to current immunotherapy, with the aim of finding new ways to improve treatment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.